Genomics

Dataset Information

0

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIPseq-ELAVL3&R1D]

ABSTRACT: ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIPseq-ELAVL3&R1D]

PROVIDER: PRJNA990712 | ENA |

REPOSITORIES: ENA

Json Xml

Similar Datasets

Other ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIPseq-ELAVL3&R1D]
2023-10-23 | GSE236365 | GEO
Transcriptomics ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIP-seq]
2023-10-23 | GSE224910 | GEO
Transcriptomics ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [NCI-H660]
2023-10-23 | GSE222469 | GEO
Transcriptomics ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [LNCaP/AR/shTP53/shRB1]
2023-10-23 | GSE224909 | GEO
Genomics ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIP-seq]
| PRJNA934547 | ENA
Genomics ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [NCI-H660]
| PRJNA922169 | ENA
Genomics ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [LNCaP/AR/shTP53/shRB1]
| PRJNA934548 | ENA
Genomics The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer
| PRJNA933106 | ENA
Genomics FOXR2 stabilizes MYCN protein and identifies non-MYCN-amplified neuroblastoma patients with unfavorable outcome
| PRJNA656764 | ENA
Transcriptomics The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer
2023-10-22 | GSE224911 | GEO